Baird raised its price target on Amedisys (NASDAQ: AMED) to $60.00 (from $50.00) while maintaining a Neutral rating following the company's 3Q release. 3Q17 revenues of $386.7m beat consensus of $385.3m by 0.4%. EBITDA of $36.9m beat consensus of $35.5m by 3.9% and EPS of $0.56 exceeded consensus at $0.53 by 5.0%.

Baird's 2017-18 EPS estimates go to $2.26 (from $2.20) and $2.53 (from $2.36). Baird is modestly above consensus on EBITDA and slightly below on EPS.